Skip to main content
An official website of the United States government

Quizartinib Dihydrochloride

Placeholder slot
 (kwih-ZAR-tih-nib dy-HY-droh-KLOR-ide)

This page contains brief information about quizartinib dihydrochloride and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.

US Brand Name(s)
FDA Approved

FDA label information for this drug is available at DailyMed.

Use in Cancer

Quizartinib dihydrochloride is approved to treat:

Quizartinib dihydrochloride is only available as part of a special program called Vanflyta REMS (Risk Evaluation and Mitigation Strategies).

More About Quizartinib Dihydrochloride

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

MedlinePlus Information on Quizartinib Dihydrochloride - A lay language summary of important information about this drug that may include the following:

  • warnings about this drug,
  • what this drug is used for and how it is used,
  • what you should tell your doctor before using this drug,
  • what you should know about this drug before using it,
  • other drugs that may interact with this drug, and
  • possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

Research Results and Related Resources

Quizartinib Approval Adds New Treatment Option for AML, Including in Older Patients

Targeted Therapy to Treat Cancer

Clinical Trials Accepting Patients

Find Clinical Trials for Quizartinib Dihydrochloride - Check for trials from NCI's list of cancer clinical trials now accepting patients.

  • Posted:
  • Updated: